PMID- 10880729
OWN - NLM
STAT- MEDLINE
DCOM- 20000918
LR  - 20191210
IS  - 0188-4409 (Print)
IS  - 0188-4409 (Linking)
VI  - 31
IP  - 2
DP  - 2000 Mar-Apr
TI  - Allogeneic bone marrow transplantation for chronic myeloid leukemia: a single 
      center experience.
PG  - 206-9
AB  - BACKGROUND: Bone marrow transplantation (BMT) is the therapy of choice for 
      patients with chronic myeloid leukemia (CML) who have a human leukocyte antigen 
      (HLA)-identical donor and are under 50 years of age. METHODS: Here, 45 patients 
      with CML were treated with busulfan (Bu) 16 mg/kg and cyclophosphamide (Cy) 120 
      mg/kg before allogeneic BMT from an HLA-identical sibling 27 (60%) or a 1-antigen 
      mismatch donor 18 (40%). Eighteen patients (40%) were in the early chronic phase 
      (CP) and 27 (60%) in late CP. We used cyclosporin-A (CsA) in 20 patients and 
      cyclosporin-A-methotrexate (CsA-MTX) in 25 for graft-vs.-host disease (GVHD) 
      prophylaxis. RESULTS: We observed a high incidence of acute and chronic GVHD (69% 
      and 67%, respectively). A multivariate analysis identified differences in the sex 
      of the donor and the recipient (p = 0.03) and grade III-IV acute GVHD (p = 
      0.0001) as significant adverse influences on disease-free survival. Age, sex, 
      chronic GVHD, disease phase, one antigen-mismatch and use of CsA or CsA-MTX had 
      no statistical significance. The 3-year probabilities of relapse, disease-free 
      survival, and overall survival were 11%, 55%, and 60%, respectively. 
      Transplant-related mortality occurred in 31% of the cases. The high frequency of 
      GVHD is explained by HLA determination by serological typing, differences in sex 
      between the donor and recipient, and a high proportion (40%) of 1 
      antigen-mismatch donors. CONCLUSIONS: BMT is a procedure feasible for patients 
      with CML in early and late chronic phase and even in those with an HLA 
      non-identical donor. Strategies directed to decrease acute GVHD could improve the 
      outcome of these patients.
FAU - Vela-Ojeda, J
AU  - Vela-Ojeda J
AD  - Departamento de Hematologia, Programa de Trasplante de Medula Osea, Hospital de 
      Especialidades, Centro Medico Nacional La Raza, Instituto Mexicano del Seguro 
      Social (IMSS), Mexico, D.F., Mexico. velaj12x@df1.telmex.net.mx
FAU - Tripp-Villanueva, F
AU  - Tripp-Villanueva F
FAU - Sanchez-Cortes, E
AU  - Sanchez-Cortes E
FAU - Ayala-Sanchez, M
AU  - Ayala-Sanchez M
FAU - Rosas-Cabral, A
AU  - Rosas-Cabral A
FAU - Esparza, M G
AU  - Esparza MG
FAU - Garcia-Chavez, J
AU  - Garcia-Chavez J
FAU - Garcia-Leon, L D
AU  - Garcia-Leon LD
FAU - Gonzalez-Llaven, J
AU  - Gonzalez-Llaven J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Arch Med Res
JT  - Archives of medical research
JID - 9312706
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Bone Marrow Transplantation/adverse effects/statistics & numerical data
MH  - Disease-Free Survival
MH  - Female
MH  - Graft vs Host Disease/etiology/mortality
MH  - Histocompatibility
MH  - Humans
MH  - Infections/etiology/mortality
MH  - Inflammation/etiology
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality/*therapy
MH  - Life Tables
MH  - Male
MH  - Mexico
MH  - Middle Aged
MH  - Philadelphia Chromosome
MH  - Premedication
MH  - Proportional Hazards Models
MH  - Recurrence
MH  - Survival Analysis
MH  - Tissue Donors
MH  - Transplantation Conditioning/adverse effects
MH  - *Transplantation, Homologous/adverse effects/statistics & numerical data
MH  - Treatment Outcome
EDAT- 2000/07/06 11:00
MHDA- 2000/09/23 11:01
CRDT- 2000/07/06 11:00
PHST- 2000/07/06 11:00 [pubmed]
PHST- 2000/09/23 11:01 [medline]
PHST- 2000/07/06 11:00 [entrez]
AID - S0188-4409(00)00071-0 [pii]
AID - 10.1016/s0188-4409(00)00071-0 [doi]
PST - ppublish
SO  - Arch Med Res. 2000 Mar-Apr;31(2):206-9. doi: 10.1016/s0188-4409(00)00071-0.